Related references
Note: Only part of the references are listed.Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with
J. M. Carrascosa et al.
ACTAS DERMO-SIFILIOGRAFICAS (2022)
Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago
Laida Elberdin et al.
DERMATOLOGY AND THERAPY (2022)
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
Zenas Z. N. Yiu et al.
JAMA DERMATOLOGY (2022)
Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1-3 genes
Beniamin Grabarek et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2021)
The comparison of effectiveness of therapy with ustekinumab and etanercept in psoriatic patients during 48 weeks' observation
Dominika Wcislo-Dziadecka et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2021)
Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital
L. Elberdin et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Z. Z. N. Yiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Analysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab
Dominika Ligia Wcislo-Dziadecka et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2020)
Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks
M. Toro-Montecinos et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab
Eline De Keyser et al.
THERAPEUTIC DRUG MONITORING (2019)
Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis
Lieke J. van Vugt et al.
JAMA DERMATOLOGY (2019)
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
Teresa Tsakok et al.
JAMA DERMATOLOGY (2019)
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis
Nick Dand et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Optimal concentration range of ustekinumab in patients with plaque-type psoriasis
Sergio Martin-Gonzalez et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Therapeutic drug monitoring of biologics in psoriasis
MeiQi May Liau et al.
BIOLOGICS-TARGETS & THERAPY (2019)
Current Practice of Therapeutic Drug Monitoring of Biopharmaceuticals in Psoriasis Patients
Caroline Hermans et al.
THERAPEUTIC DRUG MONITORING (2017)
Role of the HLA-C☆06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients
M. Talamonti et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program
Katherine Li et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value
Laida Elberdin et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2016)
The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting
S. P. Menting et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting
Eduardo Fonseca et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
Hsien-Yi Chiu et al.
PLOS ONE (2015)
Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA
Rosa Maria Fernandez-Torres et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2014)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Share Paper
